All In Biotech

Drug Trial Radar · NCT04483947

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

A Phase 1, Double Blind, Randomised, Placebo-Controlled, Multi-centre, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2693 in Patients With Non-alcoholic Steatohepatitis (NASH) With Fibrosis Stage 0-3 and Carriers of the PNPLA3 148M Risk Alleles

Last checked: Nov 19, 2026Latest source record: Jan 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

74

Actual

Start

Nov 6, 2020

Primary completion

Dec 18, 2023

Study completion Dec 18, 2023

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Jul 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with Non-alcoholic Steatohepatitis (NASH) with fibrosis Stage 0 to 3 and who are carriers of the patatin-like phospholipase domain-containing 3 (PNPLA3) 148M risk alleles.

Conditions

  • Non-alcoholic Steatohepatitis (NASH)

Interventions

  • AZD2693Drug

    Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).

  • PlaceboOther

    Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse eventsTime frame: Up to 32 weeks (From Screening to Final Visit)

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Chula Vista, California

  • Research Site

    La Mesa, California

  • Research Site

    Montclair, California

  • Research Site

    San Diego, California

  • Research Site

    Doral, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Morehead City, North Carolina

  • Research Site

    Columbus, Ohio

  • Research Site

    Hershey, Pennsylvania

  • Research Site

    Arlington, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.